Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development.

Chen TC, da Fonseca CO, Schönthal AH.

Int J Mol Sci. 2018 Dec 6;19(12). pii: E3905. doi: 10.3390/ijms19123905. Review.

2.

Preclinical development and clinical use of perillyl alcohol for chemoprevention and cancer therapy.

Chen TC, Fonseca CO, Schönthal AH.

Am J Cancer Res. 2015 Apr 15;5(5):1580-93. eCollection 2015. Review.

3.

Perillyl alcohol for the treatment of temozolomide-resistant gliomas.

Cho HY, Wang W, Jhaveri N, Torres S, Tseng J, Leong MN, Lee DJ, Goldkorn A, Xu T, Petasis NA, Louie SG, Schönthal AH, Hofman FM, Chen TC.

Mol Cancer Ther. 2012 Nov;11(11):2462-72. doi: 10.1158/1535-7163.MCT-12-0321. Epub 2012 Aug 28.

4.

Preliminary results from a phase I/II study of perillyl alcohol intranasal administration in adults with recurrent malignant gliomas.

da Fonseca CO, Schwartsmann G, Fischer J, Nagel J, Futuro D, Quirico-Santos T, Gattass CR.

Surg Neurol. 2008 Sep;70(3):259-66; discussion 266-7. doi: 10.1016/j.surneu.2007.07.040. Epub 2008 Mar 4.

PMID:
18295834
5.

Perillyl Alcohol and Its Drug-Conjugated Derivatives as Potential Novel Methods of Treating Brain Metastases.

Chen TC, Da Fonseca CO, Schönthal AH.

Int J Mol Sci. 2016 Sep 2;17(9). pii: E1463. doi: 10.3390/ijms17091463. Review.

6.

A novel temozolomide-perillyl alcohol conjugate exhibits superior activity against breast cancer cells in vitro and intracranial triple-negative tumor growth in vivo.

Chen TC, Cho HY, Wang W, Barath M, Sharma N, Hofman FM, Schönthal AH.

Mol Cancer Ther. 2014 May;13(5):1181-93. doi: 10.1158/1535-7163.MCT-13-0882. Epub 2014 Mar 12.

7.

Recent advances in the molecular genetics of malignant gliomas disclose targets for antitumor agent perillyl alcohol.

da Fonseca CO, Landeiro JA, Clark SS, Quirico-Santos T, da Costa Carvalho Mda G, Gattass CR.

Surg Neurol. 2006;65 Suppl 1:S1:2-1:8; discussion S1:8-1:9. Review.

PMID:
16427438
8.

Ras pathway activation in gliomas: a strategic target for intranasal administration of perillyl alcohol.

da Fonseca CO, Linden R, Futuro D, Gattass CR, Quirico-Santos T.

Arch Immunol Ther Exp (Warsz). 2008 Jul-Aug;56(4):267-76. doi: 10.1007/s00005-008-0027-0. Epub 2008 Jul 29.

9.

Efficacy of a ketogenic diet with concomitant intranasal perillyl alcohol as a novel strategy for the therapy of recurrent glioblastoma.

Santos JG, Da Cruz WMS, Schönthal AH, Salazar MD, Fontes CAP, Quirico-Santos T, Da Fonseca CO.

Oncol Lett. 2018 Jan;15(1):1263-1270. doi: 10.3892/ol.2017.7362. Epub 2017 Nov 8.

10.

Perillyl alcohol: Dynamic interactions with the lipid bilayer and implications for long-term inhalational chemotherapy for gliomas.

da Fonseca CO, Khandelia H, Salazar MD, Schönthal AH, Meireles OC, Quirico-Santos T.

Surg Neurol Int. 2016 Jan 5;7:1. doi: 10.4103/2152-7806.173301. eCollection 2016.

11.

Efficacy of monoterpene perillyl alcohol upon survival rate of patients with recurrent glioblastoma.

da Fonseca CO, Simão M, Lins IR, Caetano RO, Futuro D, Quirico-Santos T.

J Cancer Res Clin Oncol. 2011 Feb;137(2):287-93. doi: 10.1007/s00432-010-0873-0. Epub 2010 Apr 18.

PMID:
20401670
12.

Long-term outcome in patients with recurrent malignant glioma treated with Perillyl alcohol inhalation.

DA Fonseca CO, Teixeira RM, Silva JC, DE Saldanha DA Gama Fischer J, Meirelles OC, Landeiro JA, Quirico-Santos T.

Anticancer Res. 2013 Dec;33(12):5625-31.

PMID:
24324108
13.

Correlation of tumor topography and peritumoral edema of recurrent malignant gliomas with therapeutic response to intranasal administration of perillyl alcohol.

Da Fonseca CO, Silva JT, Lins IR, Simão M, Arnobio A, Futuro D, Quirico-Santos T.

Invest New Drugs. 2009 Dec;27(6):557-64. doi: 10.1007/s10637-008-9215-3. Epub 2009 Jan 13.

PMID:
19139816
14.

Perillyl alcohol exhibits in vitro inhibitory activity against Plasmodium falciparum and protects against experimental cerebral malaria.

Rodriguez AAM, Carvalho LJM, Kimura EA, Katzin AM.

Int J Antimicrob Agents. 2018 Mar;51(3):370-377. doi: 10.1016/j.ijantimicag.2017.08.025. Epub 2017 Aug 23.

PMID:
28843818
15.

Intranasal administration of perillyl alcohol activates peripheral and bronchus-associated immune system in vivo.

D'Alincourt Salazar M, da Silva RF, Da Fonseca CO, Lagrota-Candido J, Quirico-Santos T.

Arch Immunol Ther Exp (Warsz). 2014 Feb;62(1):59-66. doi: 10.1007/s00005-013-0262-x. Epub 2013 Nov 21.

PMID:
24257817
16.

Analysis of EGF+61A>G polymorphism and EGF serum levels in Brazilian glioma patients treated with perillyl alcohol-based therapy.

da Silveira Fd, Lopes Bde A, da Fonseca CO, Quirico-Santos T, de Palmer Paixão IC, de Amorim LM.

J Cancer Res Clin Oncol. 2012 Aug;138(8):1347-54. doi: 10.1007/s00432-012-1203-5. Epub 2012 Apr 6.

PMID:
22481252
17.

A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.

Bailey HH, Wilding G, Tutsch KD, Arzoomanian RZ, Alberti D, Feierabend C, Simon K, Marnocha R, Holstein SA, Stewart J, Lewis KA, Hohl RJ.

Cancer Chemother Pharmacol. 2004 Oct;54(4):368-76. Epub 2004 Jun 15.

PMID:
15205914
18.

Direct nose-to-brain delivery of lamotrigine following intranasal administration to mice.

Serralheiro A, Alves G, Fortuna A, Falcão A.

Int J Pharm. 2015 Jul 25;490(1-2):39-46. doi: 10.1016/j.ijpharm.2015.05.021. Epub 2015 May 12.

PMID:
25979854
20.

Perillyl alcohol-mediated inhibition of lung cancer cell line proliferation: potential mechanisms for its chemotherapeutic effects.

Xu M, Floyd HS, Greth SM, Chang WC, Lohman K, Stoyanova R, Kucera GL, Kute TE, Willingham MC, Miller MS.

Toxicol Appl Pharmacol. 2004 Mar 1;195(2):232-46.

PMID:
14998688

Supplemental Content

Support Center